Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Open
Phase 3
This trial is comparing the combination of MK-2870 and pembrolizumab with pembrolizumab on its own for non small cell lung cancer.
It is open to people with non small cell lung cancer that has spread to another part of the body.
Recruitment start: 20 June 2024
Recruitment end: 27 April 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Eleni Karapanagiotou
Merck, Sharp & Dohme LLC
Last reviewed: 16 July 2025
CRUK internal database number: 19888
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
